{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-043764","form_type":"8-K","ticker":"AARD","cik":"0001774857","company_name":"Aardvark Therapeutics, Inc.","filed_at":"2026-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.133418+00:00","generated_at":"2026-05-16T03:37:49.298943+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aardvark Therapeutics expands Phase 3 HERO trial age eligibility to 7+ years for ARD-101 in PWS","bullets":["IRB approved amended protocol lowering minimum age from 10 to 7 years for Phase 3 HERO trial evaluating ARD-101.","Amended protocol submitted to FDA; enrollment on track for topline data in Q3 2026.","Trial targets 90 patients across US, Australia, Canada, UK, and South Korea.","Primary endpoint: change in HQ-CT score at 12 weeks; open-label extension offered to completers."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-043764","json":"https://secwatch.observer/filing/0001193125-26-043764.json","markdown":"https://secwatch.observer/filing/0001193125-26-043764.md","text":"https://secwatch.observer/filing/0001193125-26-043764.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526043764/0001193125-26-043764-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526043764/ck0001774857-20260210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:37:49.298943+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}